Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Dexcel Pharma USA receives FDA approval for generic nintedanib capsules targeting idiopathic pulmonary fibrosis
Small molecule, respiratory disease, kinase inhibitor, idiopathic pulmonary fibrosis, generic drug - Read more

Vertex Pharmaceuticals, Halozyme partner on Hypercon drug delivery technology, $15M upfront plus milestones
Licensing deal, drug delivery, biologics, milestone payments - Read more

Eli Lilly, AC Immune expand Alzheimer's collaboration with $12.5M payment for tau morphomer development
Research collaboration, neurological, small molecule, milestone payments - Read more

Biogen, Alloy Therapeutics partner on multi-target ASO development with upfront payment and milestone eligibility
Research collaboration, antisense oligonucleotide, drug discovery, milestone payments - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

SonoNeu emerges stealth with $5.2M ARPA-H funding for ultrasound-based drug-free cell therapy platform
Sonogenetics, neurological, strategic, investment - Read more

E2 raises $80M Series C for next-gen thrombectomy treatment commercialization
Medical devices, thrombectomy, cardiovascular, pulmonary embolism - Read more

HexemBio raises $10.4M Seed funding, developing blood stem cell rejuvenation therapies
Regenerative medicine, cell therapy, hematopoietic stem cells, platform technology - Read more

Gilead Sciences to acquire German biotech Tubulis for $3.1B upfront in ADC deal
Antibody-drug conjugate, oncology, strategic, major transaction - Read more

Fortrea launches AI-powered FIT suite to automate workflows and improve clinical trial efficiency
Technology platform, operational, strategic, competitive - Read more

AbbVie offers Humira on TrumpRx platform at 86% discount for $950 amid tariff exemption deal
Monoclonal antibody, autoimmune, strategic, cost reduction - Read more

FDA's 2027 budget proposes permanent rare disease vouchers and streamlined Phase 1 trial entry pathway
Rare disease, regulatory, strategic, operational - Read more

FDA seeks broader authority to police misleading drug ads and streamline biosimilar approvals in budget request
Biosimilar, regulatory, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Merck & Co., Chongqing Zhifei Biological Products adjust China vaccine partnership, removing minimum purchase commitments amid Gardasil demand decline
Manufacturing agreement, vaccine, infectious disease, supply chain - Read more

Sanofi's lunsekimig (dual-acting drug) shows mixed Ph2 results in asthma and chronic rhinitis versus atopic dermatitis
Antibody, respiratory disease, dual targeting therapy, asthma, TSLP inhibition, IL-13 inhibition - Read more

Insmed halts Brinsupri (brensocatib) development for hidradenitis suppurativa after Ph2 trial fails primary endpoint
Small molecule, inflammatory disease, DPP1 inhibitor, hidradenitis suppurativa - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here